• Myeloma UK
  • Clinical Service Excellence Programme
Myeloma Academy
Sign inRegister
Menu
  • Home
  • CPD & Learning
    • Myeloma Nurse Learning Programme
    • My CPD Portfolio
    • Challenging Cases
    • Close
  • Library
    • Guidelines
      • Complications
      • COVID-19 guidance
      • General haemato/oncology
      • Imaging & Analysis
      • Management & Treatment
      • Palliative Care
      • Presentation & Diagnosis
      • Related conditions
      • Close
    • Patient Support and Information
    • Medical animations
    • Close
  • Resources
    • Myeloma Drug Finder
    • Myeloma Trial Finder
    • Assessment tools
    • Myeloma Spotlight
    • Primary care education
    • Secondary care education
    • Myeloma health economic model
    • Close
  • News & Events
    • News
    • Event calendar
    • Meeting highlights
    • Close
  • CSEP
  • About Us
    • Contact Us
    • Close
Menu back  
 

Current treatments

A phase 2 study of three low-dose intensity subcutaneous Bortezomib regimens in elderly frail patients with untreated multiple myeloma.
Larocca A et al. Leukemia. 2016 Feb 22. doi: 10.1038/leu.2016.36. [Epub ahead of print].

A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone.
Zwickl H et al. Leuk Lymphoma. 2016 Feb 22:1-6. [Epub ahead of print].

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom MyelomaForum Myeloma X (Intensive) Trial.
Parrish C et al. Biol Blood Marrow Transplant. 2016 Jan 28. pii: S1083-8791(16)00056-2. doi: 10.1016/j.bbmt.2016.01.016. [Epub ahead of print]

High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.
Nath CE et al. Br J Clin Pharmacol. 2016 Feb 15. doi: 10.1111/bcp.12906. [Epub ahead of print].

Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractorymultiple myeloma: MM-024 Extended Access Program.
Du X et al. BMC Cancer. 2016 Jan 28;16(1):46. doi: 10.1186/s12885-016-2069-8.

 

 

  • Guidelines
  • Patient Support and Information
  • Medical animations
Bottom menu

Charity No. SC 026116
Myeloma UK
22 Logie Mill
Beaverbank Business Park
Edinburgh
EH7 4HG